Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus POLARAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus POLARAMINE.
BROMPHENIRAMINE MALEATE vs POLARAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Category C
Category C
Antihistamine
Antihistamine